EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serelaxin has greater anti-fibrotic potential than perindopril but maintains its anti-fibrotic efficacy in the presence of perindopril in normotensive mouse models of heart disease

Ziqiao Wang, Gang She, Chao Wang, Dorota Ferens, Ekaterina Salimova, Robert E Widdop, Tracey A Gaspari, Chrishan S Samuel

Life Sciences · 2026-08 · 399 · 124472

DOI: 10.1016/j.lfs.2026.124472 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Sciences, 2026-08. Verfasst von Ziqiao Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Fibrosis Group, Department of Pharmacology and Cardiovascular Disease Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria,…. Hauptthemen laut MEDLINE: Relaxin, Perindopril, Antifibrotic Agents, Heart Diseases. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Monash University Monash Biomedicine Discovery Institute, Bundesverband der Deutschen Industrie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RelaxinPerindoprilAntifibrotic AgentsHeart DiseasesAnimalsMiceFibrosisDisease Models, AnimalAngiotensin-Converting Enzyme InhibitorsMaleBlood PressureRecombinant ProteinsMice, Inbred C57BLMyocardial InfarctionCardiomyopathiesDose-Response Relationship, DrugIsoproterenolDrug Therapy, CombinationHumans

Stichwörter der Autor:innen

ACEiCardiomyopathyFibrosisMyocardial infarctionRXFP1Relaxin

Substanzen

RelaxinPerindoprilAngiotensin-Converting Enzyme Inhibitorsserelaxin protein, humanRecombinant ProteinsAntifibrotic AgentsIsoproterenol

Autor:innen und Institutionen

  • Fibrosis Group, Department of Pharmacology and Cardiovascular Disease Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
  • Fibrosis Group, Department of Pharmacology and Cardiovascular Disease Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia; Department of Physiology and Pathophysiology, School of Ba…
  • Integrative Cardiovascular Pharmacology Group, Department of Pharmacology and Cardiovascular Disease Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
  • Monash Biomedical Imaging, Monash University, Clayton, Victoria, Australia.
  • Fibrosis Group, Department of Pharmacology and Cardiovascular Disease Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia. Electronic address: chrishan.samuel@monash.edu.

Förderung

  • Monash University Monash Biomedicine Discovery Institute
  • Bundesverband der Deutschen Industrie

Zitieren

APA

Wang, Z., She, G., Wang, C., Ferens, D., Salimova, E., Widdop, R. E., Gaspari, T. A., & Samuel, C. S. (2026). Serelaxin has greater anti-fibrotic potential than perindopril but maintains its anti-fibrotic efficacy in the presence of perindopril in normotensive mouse models of heart disease. Life Sciences, 399, 124472. https://doi.org/10.1016/j.lfs.2026.124472

Vancouver

Wang Z, She G, Wang C, Ferens D, Salimova E, Widdop RE, et al. Serelaxin has greater anti-fibrotic potential than perindopril but maintains its anti-fibrotic efficacy in the presence of perindopril in normotensive mouse models of heart disease. Life Sciences. 2026;399:124472. doi:10.1016/j.lfs.2026.124472

BibTeX
@article{Wang2026,
  author = {Wang, Ziqiao and She, Gang and Wang, Chao and Ferens, Dorota and Salimova, Ekaterina and Widdop, Robert E and Gaspari, Tracey A and Samuel, Chrishan S},
  title = {Serelaxin has greater anti-fibrotic potential than perindopril but maintains its anti-fibrotic efficacy in the presence of perindopril in normotensive mouse models of heart disease},
  journal = {Life Sciences},
  year = {2026},
  volume = {399},
  pages = {124472},
  doi = {10.1016/j.lfs.2026.124472}
}
Kostenlos starten →